Trial Profile

A Pilot Study to Assess the Use of Methylone in the Treatment of PTSD IMPACT-1 (Investigation of Methylone for Post-Traumatic Stress Disorder [PTSD])

Status: Completed

Phase of Trial: Phase I/II

Latest Information Update: 21 Apr 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Methylone (Primary)
Indications Post-traumatic stress disorders
Focus Therapeutic Use
Acronyms IMPACT-1
Sponsors Transcend Therapeutics

Most Recent Events

31 Mar 2025 Primary endpoint has been met. (Change from Baseline in Clinician-Administered PTSD Scale for the DSM-5 (CAPS-5) total severity score)
31 Mar 2025 Results presented in a Transcend Therapeutics media release.
16 Mar 2025 Status changed from active, no longer recruiting to completed.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com